|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Tacrolimus**(N = 43) | **CsA**(N = 24) | **Difference in mean****(95% CI)** | ***P*-value**(*t*-test) |
| *Rday\_20* | 62% (± 37%) | 48% (± 41%) | 14%(-6.0%–33%) | 0.17 |
| *Rday\_30* | 66% (± 31%) | 56% (± 34%) | 9.4%(-6.9%–26%) | 0.25 |
| *Rday\_40* | 62% (± 29%) | 54% (± 31%) | 7.8%(-7.2%–23%) | 0.30 |
| *Rday\_50* | 57% (± 29%) | 50% (± 29%) | 7.2%(-7.6%–22%) | 0.34 |

**S7 Table. Relation between GVHD prophylaxis & *Rday\_n* (n = 20, 30, 40, and 50 days)**

Estimated values and standard deviations of each *Rday\_n* (n = 20, 30, 40, and 50) are shown. Estimated differences mean of *Rday\_n* (n = 20, 30, 40, and 50) and these 95% confidence intervals are also shown. Results of statistical tests and *P*-values are also shown. CsA means cyclosporine A.